A Phase I clinical trial evaluating an engineered CD40 agonistic antibody (2141.V11) demonstrated promising anti-tumor activity in 12 metastatic cancer patients, including melanoma and breast cancer. Half of the patients experienced tumor shrinkage, with complete remission observed in two cases. The treatment delivered intratumorally induced systemic immune responses affecting distant tumors, marking a rare and noteworthy outcome in oncology. This study was published in Cancer Cell and led by researchers at Rockefeller University and Memorial Sloan Kettering Cancer Center.